Aspects of the present application relate to solid forms of Omecamtiv mecarbil dihydrochloride. Specific aspects relate to crystalline forms and amorphous solid dispersions of Omecamtiv mecarbil dihydrochloride. Further specific aspects related to crystalline forms DP1, DP2, DP3, DP4, OMT-D, OMT-L, OMT-O, OMT-F, OMT-FS and amorphous solid dispersions of Omecamtiv mecarbil dihydrochloride and pharmaceutical compositions thereof.

This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity.

The present invention relates to solid dispersions comprising a salt of ursolic acid with an alkali metal and a phospholipid and to oral dosage formulations containing them. The invention also relates to processes for preparing the solid dispersions and to the use of the solid dispersions and formulations for the prevention and/or treatment of a variety of pathological conditions in which hepatoprotective, antioxidant, anti-inflammatory, antiviral and cytotoxic activities are desired.

A method for preparing a microsphere include steps of dissolving an active ingredient and a biodegradable polymer in an organic solvent to prepare a dispersed phase, dissolving a salt in water to prepare a continuous phase, mixing and stirring the dispersed phase and the continuous phase to form an emulsion, removing the organic solvent; and drying.

A solid particulate formulation comprising soluble ferric pyrophosphate and a sachet comprising the solid particulate formulation of soluble ferric pyrophosphate for adding to a dialysis solution are provided. Improved methods of administering soluble ferric pyrophosphate comprising the solid particulate formulations and kits comprising the solid particulate formulation and a dialysis concentrate formulation are also disclosed.

The present invention relates to a method for granulating an amphiphilic active ingredient or a pharmaceutically acceptable salt thereof, comprising a step for coating the active ingredient in a polar aprotic solvent in the presence of a polymer binder to obtain a granule.

This invention relates to a method and composition for balancing the bile acid profile in the intestine of humans, particularly decreasing primary bile acids and/or increasing production of secondary bile acids.

Multiparticulate compositions including an active agent and a gelling agent are disclosed. The multiparticulate compositions are prepared by an aqueous-based spray and congeal process.

The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.

The invention relates to particles of a mixture of iron(III)-oxyhydroxide, sucrose and one or more starches, preferably of sucroferric oxyhydroxide having a certain particle size distribution, a process for the manufacture thereof, the pharmaceutical composition comprising the same, in particular compressed tablets.